个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共10条记录   Innovative therapeutical approaches for hematological malignancies based on molecular targeted therapies [作者：Zauli, G,期刊：Current Pharmaceutical Design, 页码：2022-2022 , 文章类型： Editorial Material，,卷期：2008年14-21] An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies [作者：Macor, P; Secco, E; Zorzet, S; Tripodo, C; Celeghini, C; Tedesco, F,期刊：Current Pharmaceutical Design, 页码：2023-2039 , 文章类型： Review，,卷期：2008年14-21] B-cell malignancies account for over the 90% of all lymphoid neoplasms. The clonal proliferations of B-cells show a high degree of variation in terms of clinical and presenting features, histopathology, immuophenotype, a... Potential therapeutic applications of miRNA-based technology in hematological malignancies [作者：Barbarotto, E; Calin, GA,期刊：Current Pharmaceutical Design, 页码：2040-2050 , 文章类型： Review，,卷期：2008年14-21] MicroRNAs (miRNAs) are an abundant class of approximately 22-nucleotide-noncoding RNAs, which play important regulatory roles in animal and plant development: they are involved in gene expression at the posttranscription... Targeting cyclooxygenase-2 in hematological malignancies: Rationale and promise [作者：Bernard, MP; Bancos, S; Sime, PJ; Phipps, RP,期刊：Current Pharmaceutical Design, 页码：2051-2060 , 文章类型： Review，,卷期：2008年14-21] There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclo... Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects [作者：van Blitterswijk, WJ; Verheij, M,期刊：Current Pharmaceutical Design, 页码：2061-2074 , 文章类型： Review，,卷期：2008年14-21] Synthetic anticancer alkylphospholipids (APLs), such as edelfosine, miltefosine and perifosine, are a group of structurally related lipids that act on cellular membranes rather than the DNA. APLs have essentially one lon... Potential role of PKC inhibitors in the treatment of hematological malignancies [作者：Mischiati, C; Melloni, E; Corallini, F; Milani, D; Bergamini, C; Vaccarezza, M,期刊：Current Pharmaceutical Design, 页码：2075-2084 , 文章类型： Review，,卷期：2008年14-21] The serine/threonine protein kinase C (PKC) family, the main target of tumor-promoting phorbol esters, is functionally associated to cell cycle regulation, cell survival, malignant transformation, and tumor angiogenesis.... A combined approach with rituximab plus Anti-TRAIL-R agonistic antibodies for the treatment of haematological malignancies [作者：Sancilio, S; Grill, V; Di Pietro, R,期刊：Current Pharmaceutical Design, 页码：2085-2099 , 文章类型： Review，,卷期：2008年14-21] Molecular targeted therapies have changed the landscape of cancer research. Agonistic monoclonal antibodies (MoAbs) targeting TRAIL-death receptors (TRAIL-Rs) have been developed and currently used in clinical trials. Bi... The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies [作者：Secchiero, P; di Iasio, MG; Gonelli, A; Zauli, G,期刊：Current Pharmaceutical Design, 页码：2100-2110 , 文章类型： Review，,卷期：2008年14-21] At variance to solid tumors, which show percentage of p53 deletions and/or mutations close to 50%, more than 80% of haematological malignancies express wild-type p53 at diagnosis. Therefore, activation of the p53 pathway... Drug eluting stents and beyond [作者：Rastogi, A; Stavchansky, S,期刊：Current Pharmaceutical Design, 页码：2111-2120 , 文章类型： Review，,卷期：2008年14-21] The present review discusses the mechanism of late stent thrombosis and its distinction from restenosis and summarizes the advisory note issued by FDA on the proper usage of different treatments available for atheroscler... Metformin in the treatment of polycystic ovary syndrome [作者：Motta, DAB,期刊：Current Pharmaceutical Design, 页码：2121-2125 , 文章类型： Review，,卷期：2008年14-21] Polycystic ovary syndrome (PCOS) is one of the most frequent diseases that affects women in their reproductive age. The heterogeneity of PCOS makes not only the diagnosis but also the choice of an adequate treatment diff...